DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy

Abstract

ObjectiveWe investigated the correlation between ploidy or S-phase fraction (SPF) and the clinical pathological characteristics of patients with peritoneal carcinomatosis from ovarian cancer. We also assessed their relation with the in vivo and in vitro response to several chemotherapeutic agents.Patients and methodsFifty-three patients with peritoneal carcinomatosis from ovarian cancer were enrolled. Frozen tumor tissue was dissociated by a detergent–trypsin method, and the resulting cell suspension was stained with RNase A and propidium iodide. Samples were then analyzed for ploidy and SPF by flow cytometry. Fresh tumor tissue was dissociated by enzymatic digestion, and cells were exposed to different concentrations of cisplatin, adriamycin, carboplatin, gemcitabine and taxol for 72 hours. In vitro drug sensitivity was then measured using the sulforhodamine B assay.ResultsNo significant correlation was found between ploidy or SPF and patient characteristics, even though primary carcinomas were mainly hyperdiploid and more proliferative than recurrent tumors. SPF differed significantly among ploidy categories (P=0.01), and high SPF was associated with short-term survival (P=0.48). Patients with multiploid tumors were the most resistant to platinum-based chemotherapy, whereas those with hyperdiploid tumors were the most responsive. In vitro multiploid tumors were the least sensitive, while hypodiploid samples showed the highest sensitivity to the tested drugs. Sensitivity to adriamycin was significantly correlated with ploidy (P=0.03), whereas sensitivity to taxol was correlated with SPF (P=0.04).ConclusionOur results indicate that ploidy and SPF could facilitate the choice of therapy for patients with peritoneal carcinomatosis.

The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non‐small‐cell lung cancer

“…In fact, this concept was utilised very early in the DNA index (DI), that is, the ratio of the actual DNA content of the target sample to the DNA content of normal diploid cells. If the ratio is outside the diploid and tetraploid stages, the sample is defined as aneuploid, 22,26 such as haploid, triploid and polyploid. Normal cells have a relatively constant DNA content, but structural and/or chromosomal abnormalities are common during cell carcinogenesis.…”

“…Different types of ploidy have different effects on the occurrence and development of tumors 19 . The overall prognosis of patients with polyploid tumors is poor, 20,21 and polyploid tumors are more malignant than haploid or diploid tumors 22,23 . However, analysis of the entire chromosome can be only used for the qualitative analysis of tumor specimens, and such analysis cannot provide specific values like TMB for the quantitative analysis of different specimens, but it can be good for predicting the therapeutic effect.…”

Does DNA ploidy and synthesis phase dynamic accentuate the predictive power of oestrogen and progesterone receptors in breast cancer progression and prognosis?

“…Furthermore, they found most glioblastomas to be aneuploidy. However, Carloni et al (2017) found that DNA ploidy was not related to SPF in . They found hyperdiploidy was encountered more frequently in primary carcinomas than in recurrent tumours.…”

Minimally Invasive Cytopathology and Accurate Diagnosis: Technical Procedures and Ancillary Techniques

“…The techniques are applied on gastroscopy, esophagoscopy, tumor flushing fluid, urine and a small amount of tissue, to analyze the cell cycle state and tumor cell alloploidy, one of the most important indicators for differentiating benign and malignant tumors and determining early diagnosis of tumors (83). In parallel, DNA ploidy of tumor cells is analyzed, and the detection rate of DNA ploidy of tumor cells is closely related to clinical biological behaviors such as tumor diffusion and metastasis (84). However, a study has suggested that DNA ploidy alone is nonspecific and may not be a good tool for assessing oral cancer prognosis or metastatic progression (85).…”